Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Palobiofarma (Details)

v3.21.2
Royalty Purchase Agreements - Palobiofarma (Details)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 26, 2019
USD ($)
item
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Agreements      
Payments to acquire milestones and royalties   $ 20,500  
Long-term royalty receivables   55,075 $ 34,575
Impairment of long-term royalty receivable   0 $ 0
Palobiofarma, S.L {Member] | Royalty Purchase Agreement [Member]      
Agreements      
Number of drug candidates | item 6    
Payments to acquire milestones and royalties $ 10,000    
Long-term royalty receivables 10,000    
Impairment of long-term royalty receivable   $ 0  
Palobiofarma, S.L {Member] | Royalty Purchase Agreement [Member] | Silicon Valley Bank [Member]      
Agreements      
Proceeds from issuance of long-term debt $ 5,000